Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPALACHES adjuvant palbociclib versus chemotherapy in older patients with high-risk ER-positive/HER2-negative early breast cancer
2023-505223-31-00Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of palbociclib and adjuvant chemotherapy in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: 3-year distant recurrence-free interval rate in the experimental arm. Started Jun 2019; status: completed.
02
Drugs
palbociclibadjuvant chemotherapy
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505223-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505223-31-00.